Insights

  • Date

  • Content Type

  • Reset

Blog

The rise of Bayesian statistics in rare disease evidence gathering

16.01.23
Regulators are becoming more open to alternative data sources in the context of rare disease
Read More

Blog

Enabling Access Through Innovation – Cell and Gene Therapy in 2023 and Beyond

16.01.23
Dr. Jörg Schneider, Director – Principal Consultant at BioPharma Excellence, previews the opening plenary session
Read More

Blog

The next breakthrough: using Cell Therapies to treat solid tumors

1.01.23

By Cori Gorman, Ph.D.

Cell therapy has advanced both in the clinic and in drug approvals. Research is focused on two approaches to...
Read More

Blog

What a year! Biopharma Excellence has been easing the path to market for a whole host of advanced therapies and biosimilars

28.11.22
by Dr. Christian K Schneider Head of Biopharma Excellence   As Biopharma Excellence marks its
Read More

Blog

The big gene edit: the view from the front line

9.11.22

By Tim Farries, PhD

Reflections on a lively panel debate at the 2022 Cell & Gene Meeting on the
Read More

Blog

Bringing vaccine equity to Africa through ‘tech and reg’ transfer

8.11.22
Michael Pfleiderer, Ph.D., Principal Consultant and Senior Director Efforts to address Covid-19 worldwide through vaccination
Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more